You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
An innovative telomerase-targeted, circulating tumor cell assay for monitoring NSCLC treated with radiation and immunotherapy
SBC: Liquid Biotech USA, Inc. Topic: 102Project Summary: Cancer is a leading cause of death both in the United States and across the world, claiming over 600,000 and 8 million deaths each year, respectively. Delayed detection of cancer progression or recurrence after treatment contributes to increased morbidity and rapid death, but re-biopsy or repeat surgery is usually not possible due to severe risks. The accuracy of conventional imag ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a PCR assay for quantitative detection of HBV cccDNA
SBC: JBS SCIENCE INC Topic: NIAIDDevelopment of a PCR assay for quantitative detection of HBV cccDNA There is an urgent and unmet need for an effective method to detect hepatitis B virus (HBV) cccDNA in the blood. HBV infection affects nearly 350 million people worldwide. Chronic HBV infection is a major risk factor for the development of severe liver diseases such as cirrhosis and hepatocellular carcinoma, which has a poor survi ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Trypanocidal Agents that Kill Multiple Stages of the Trypanosoma cruzi Life Cycle
SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC. Topic: NIAIDAbstract. Chagas disease is a neglected tropical disease and has been designated as a research priority by NIAID and an SBIR Research Topic of Interest. Six million individuals are infected and 8,000 deaths were caused by Chagas in 2015 in mostly Central and South America by advanced forms of the disease such as Chagas hemorrhagic fever. The cost associated with Chagas disease treatment globally i ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
A single antiviral to treat multiple opportunistic infections
SBC: EVRYS BIO LLC Topic: NIAIDPROJECT SUMMARY/ABSTRACT Immunosuppressed transplant patients have heightened susceptibility to environmental pathogens as well as adventitious agents traveling with donor tissues or resident in the recipient. Traditional therapies target the virus and are thereby limited in effectiveness to the specific virus targeted. Evrys Bio is developing orally administered, broad-spectrum antivirals that ta ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Development of a tele-mentoring system integrated into an ultra-portable surgical microscope to treat cataract in underserved populations
SBC: X-BIOMEDICAL INC Topic: NEICurrently, in austere environments like the rural regions of Africa, there are millions of people who go blind each year due to cataract. This is an easily preventable condition if they receive the correct treatment in a timely manner. Unfortunately, there is a growing shortage of ophthalmologists and other surgeons throughout the world, and in many African countries unsupervised non-physicians pe ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Combined Pro-Plasticity Reprogramming Strategies to Enhance Post-Infarction Myocardial Recovery
SBC: XYLOCOR THERAPEUTICS INC Topic: NHLBIAbstract Congestive heart failure (CHF) caused by a loss of cardiac function typically due to infarction (MI) remains the leading cause of death in the West. Current therapies for CHF including heart transplant are highly costly and invasive and still yield five-year mortality rates of 50%. Stem cell therapy for CHF has yielded disappointing results, likely due to inadequate implant engraftment in ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Discovering novel small molecule drugs through tandem mass spectral database search
SBC: CHEMIA BIOSCIENCES, INC. Topic: 400Project Summary. Natural products are the major source of drug molecules. Currently, 64% of small molecule drugs approved by the Food and Drug Administration are natural products or their derivatives. Currently, the dominant technique for discovering novel natural products is bioactivity-guided isolation. However, this technique is limited to the high abundance molecular products of microbial / pl ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Computational prediction of RNA splicing defects and rescue by small-molecule therapeutics
SBC: Panorama Medicine Inc Topic: 400PROJECT SUMMARYPanorama has developed a groundbreaking platform that combines big data and genetic sequencing to identify the RNA sequence of splice events, a cause of up to 50% of genetic diseases. These events are believed to be the cause of diseases such as Becker muscular dystrophy, Duchenne muscular dystrophy (DMD), spinal muscular atrophy (SMA), and amyotrophic lateral sclerosis (ALS). The p ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Novel Approaches for Tau PROTAC Drug Discovery
SBC: LIFESENSORS, INC. Topic: NIANovel Approaches for Tau PROTAC Drug Discovery Alzheimer’s disease (AD), frontotemporal dementia (FTD), progressive supranuclear palsy (PSP) are a group of neurodegenerative diseases characterized by the pathological accumulation of hyper-phosphorylated tau (P-tau) protein, in the form of intracellular paired helical filaments (PHFs) or neurofibrillary tangles (NFTs), or aggregates, within neuro ...
SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
On-cell screening of mouse hybridomas for improved monoclonal antibody discovery
SBC: OCMS BIO LLC Topic: 300SUMMARY OCMS Bio, LLC is seeking to revolutionize monoclonal antibody (mAb) discovery and screening through the development of an on-cell monoclonal antibody (OCMS) screening platform, an innovative cell-based approach to substantially improve the hybridoma method for antibody discovery. Monoclonal antibodies have become essential elements in modern clinical therapeutics, diagnostics, and biomedic ...
SBIR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health